Details for Patent: 11,369,599

Which drugs does patent 11,369,599 protect, and when does it expire?

Patent 11,369,599 protects VENCLEXTA and is included in one NDA.

This patent has sixty-five patent family members in thirty-nine countries.

Summary for Patent: 11,369,599

Title:	Melt-extruded solid dispersions containing an apoptosis-inducing agent
Abstract:	A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.
Inventor(s):	Birtalan; Esther (Karlsruhe, DE), Hoelig; Peter (Waechtersbach, DE), Lindley; David J. (Antioch, IL), Sanzgiri; Yeshwant D. (Gurnee, IL), Tong; Ping (Libertyville, IL)
Assignee:	AbbVie Inc. (North Chicago, IL) AbbVie Deutschland GMBH & Co KG (Wiesbaden, DE)
Application Number:	14/340,435
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 11,369,599

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-001	Apr 11, 2016		RX	Yes	No			Y
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-002	Apr 11, 2016		RX	Yes	No			Y
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes			Y

International Family Members for US Patent 11,369,599

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	083656
Argentina	122475
Australia	2011361704